A genetics-led approach defines the drug target landscape of 30 immune-related traits

Most candidate drugs currently fail later-stage clinical trials, largely due to poor prediction of efficacy on early target selection(1). Drug targets with genetic support are more likely to be therapeutically valid(2,3). The translational use of genome-scale data such as from genome-wide associatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Genet
Principais autores: Fang, Hai, De Wolf, Hans, Knezevic, Bogdan, Burnham, Katie L., Osgood, Julie, Sanniti, Anna, Lledó Lara, Alicia, Kasela, Silva, De Cesco, Stephane, Wegner, Jörg K., Handunnetthi, Lahiru, McCann, Fiona E., Chen, Liye, Sekine, Takuya, Brennan, Paul E., Marsden, Brian D., Damerell, David, O’Callaghan, Chris A., Bountra, Chas, Bowness, Paul, Sundström, Yvonne, Milani, Lili, Berg, Louise, Göhlmann, Hinrich W., Peeters, Pieter J., Fairfax, Benjamin P., Sundström, Michael, Knight, Julian C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124888/
https://ncbi.nlm.nih.gov/pubmed/31253980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41588-019-0456-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados